Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Cerity Partners LLC

Cerity Partners LLC increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 129.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,994 shares of the biotechnology company’s stock after buying an additional 15,777 shares during the quarter. Cerity Partners LLC’s holdings in Exelixis were worth $726,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Tidal Investments LLC increased its holdings in shares of Exelixis by 10.0% in the first quarter. Tidal Investments LLC now owns 9,710 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 886 shares during the period. Cetera Advisors LLC acquired a new position in Exelixis in the 1st quarter worth approximately $327,000. GAMMA Investing LLC raised its position in Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares during the last quarter. CWM LLC lifted its stake in Exelixis by 27.4% during the 2nd quarter. CWM LLC now owns 19,988 shares of the biotechnology company’s stock valued at $449,000 after acquiring an additional 4,301 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Exelixis in the 2nd quarter valued at $489,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Dana Aftab sold 1,162 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the transaction, the executive vice president now owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 41,588 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the sale, the executive vice president now directly owns 288,665 shares in the company, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 339,736 shares of company stock valued at $11,508,610 in the last 90 days. Company insiders own 2.85% of the company’s stock.

Exelixis Trading Down 0.6 %

Shares of NASDAQ EXEL opened at $35.82 on Friday. The stock has a market cap of $10.23 billion, a PE ratio of 22.96, a P/E/G ratio of 0.89 and a beta of 0.52. The company has a 50-day moving average of $31.77 and a 200 day moving average of $26.59. Exelixis, Inc. has a 12-month low of $19.20 and a 12-month high of $36.97.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the prior year, the business earned $0.10 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. On average, sell-side analysts forecast that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on EXEL shares. Stephens boosted their target price on shares of Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price target on shares of Exelixis in a report on Wednesday, October 30th. Stifel Nicolaus upped their price objective on Exelixis from $26.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, October 16th. Morgan Stanley increased their price target on shares of Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, October 11th. Finally, Bank of America lifted their price objective on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.44.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.